On October 21, 2025, Cardio Diagnostics Holdings, Inc. (CDIO) announced that it has partnered with 15 new provider organizations nationwide, expanding the adoption of its AI‑driven epigenetic‑genetic blood tests, Epi+Gen CHD™ and PrecisionCHD™. The announcement, issued via Business Wire, states that the new partners will integrate these tests into their practices to obtain actionable insights into coronary heart disease risk and guide personalized treatment plans.
The 15 new provider organizations span four major U.S. regions—Northeast, South, Midwest, and West—and represent a mix of concierge, functional medicine, and direct primary care practices. This breadth of care models demonstrates that providers across the healthcare spectrum recognize the value of CDIO’s precision approach and are willing to incorporate its tests into diverse clinical settings.
CEO and Co‑Founder Meesha Dogan, Ph.D., said the expansion reflects the strong momentum the company is building in the provider community. She added that equipping these practices with Epi+Gen CHD™ and PrecisionCHD™ will enhance patient care, drive better outcomes, and make precision cardiovascular medicine accessible to more patients nationwide.
The addition of 15 new provider partners is a significant milestone for CDIO, as it increases potential test volume, broadens market reach, and supports the company’s commercialization strategy for its epigenetic‑genetic diagnostics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.